

# Global Drugs for Treating Hyperuricemia Market Growth 2026-2032

<https://marketpublishers.com/r/G49ED5DD27EBEN.html>

Date: February 2026

Pages: 115

Price: US\$ 3,660.00 (Single User License)

ID: G49ED5DD27EBEN

## Abstracts

The global Drugs for Treating Hyperuricemia market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

Drugs used to treat hyperuricemia, a condition characterized by elevated levels of uric acid in the blood, primarily aim to lower uric acid levels to prevent complications such as gout and kidney stones. The most common medications include xanthine oxidase inhibitors like allopurinol and febuxostat, which reduce uric acid production by inhibiting the enzyme responsible for its formation. Another class, uricosuric agents such as probenecid, work by increasing uric acid excretion through the kidneys.

United States market for Drugs for Treating Hyperuricemia is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Drugs for Treating Hyperuricemia is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Drugs for Treating Hyperuricemia is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Drugs for Treating Hyperuricemia players cover Teva, Mylan Pharmaceuticals, Takeda Pharmaceuticals, Sanwa Kagaku Kenkyusho, Towa Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the "Drugs for Treating

Hyperuricemia Industry Forecast” looks at past sales and reviews total world Drugs for Treating Hyperuricemia sales in 2025, providing a comprehensive analysis by region and market sector of projected Drugs for Treating Hyperuricemia sales for 2026 through 2032. With Drugs for Treating Hyperuricemia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Drugs for Treating Hyperuricemia industry.

This Insight Report provides a comprehensive analysis of the global Drugs for Treating Hyperuricemia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for Treating Hyperuricemia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drugs for Treating Hyperuricemia market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Treating Hyperuricemia and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Treating Hyperuricemia.

This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Treating Hyperuricemia market by product type, application, key manufacturers and key regions and countries.

### **Segmentation by Type:**

Uric Acid Production Inhibitors

Urate-stimulating Excretion Agents

Other

### **Segmentation by Application:**

Hospitals and Clinics

Retail Pharmacies

Other

**This report also splits the market by region:**

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Teva

Mylan Pharmaceuticals

Takeda Pharmaceuticals

Sanwa Kagaku Kenkyusho

Towa Pharmaceutical

Toa Eiyo

AstraZeneca

Mochida Pharmaceutical

Lannett Company

Horizon Therapeutics

Sanofi

GSK

Fuji Yakuhin

### **Key Questions Addressed in this Report**

What is the 10-year outlook for the global Drugs for Treating Hyperuricemia market?

What factors are driving Drugs for Treating Hyperuricemia market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Drugs for Treating Hyperuricemia market opportunities vary by end market size?

How does Drugs for Treating Hyperuricemia break out by Type, by Application?

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

#### 2.1 World Market Overview

- 2.1.1 Global Drugs for Treating Hyperuricemia Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for Drugs for Treating Hyperuricemia by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Drugs for Treating Hyperuricemia by Country/Region, 2021, 2025 & 2032

#### 2.2 Drugs for Treating Hyperuricemia Segment by Type

- 2.2.1 Uric Acid Production Inhibitors
- 2.2.2 Urate-stimulating Excretion Agents
- 2.2.3 Other
- 2.2.4 Drugs for Treating Hyperuricemia Sales by Type
  - 2.2.4.1 Global Drugs for Treating Hyperuricemia Sales Market Share by Type (2021-2026)
  - 2.2.4.2 Global Drugs for Treating Hyperuricemia Revenue and Market Share by Type (2021-2026)
  - 2.2.4.3 Global Drugs for Treating Hyperuricemia Sale Price by Type (2021-2026)

#### 2.3 Drugs for Treating Hyperuricemia Segment by Application

- 2.3.1 Hospitals and Clinics
- 2.3.2 Retail Pharmacies
- 2.3.3 Other
- 2.3.4 Drugs for Treating Hyperuricemia Sales by Application
  - 2.3.4.1 Global Drugs for Treating Hyperuricemia Sale Market Share by Application (2021-2026)
  - 2.3.4.2 Global Drugs for Treating Hyperuricemia Revenue and Market Share by

Application (2021-2026)

2.3.4.3 Global Drugs for Treating Hyperuricemia Sale Price by Application  
(2021-2026)

### **3 GLOBAL BY COMPANY**

3.1 Global Drugs for Treating Hyperuricemia Breakdown Data by Company

3.1.1 Global Drugs for Treating Hyperuricemia Annual Sales by Company (2021-2026)

3.1.2 Global Drugs for Treating Hyperuricemia Sales Market Share by Company  
(2021-2026)

3.2 Global Drugs for Treating Hyperuricemia Annual Revenue by Company (2021-2026)

3.2.1 Global Drugs for Treating Hyperuricemia Revenue by Company (2021-2026)

3.2.2 Global Drugs for Treating Hyperuricemia Revenue Market Share by Company  
(2021-2026)

3.3 Global Drugs for Treating Hyperuricemia Sale Price by Company

3.4 Key Manufacturers Drugs for Treating Hyperuricemia Producing Area Distribution,  
Sales Area, Product Type

3.4.1 Key Manufacturers Drugs for Treating Hyperuricemia Product Location  
Distribution

3.4.2 Players Drugs for Treating Hyperuricemia Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

### **4 WORLD HISTORIC REVIEW FOR DRUGS FOR TREATING HYPERURICEMIA BY GEOGRAPHIC REGION**

4.1 World Historic Drugs for Treating Hyperuricemia Market Size by Geographic Region  
(2021-2026)

4.1.1 Global Drugs for Treating Hyperuricemia Annual Sales by Geographic Region  
(2021-2026)

4.1.2 Global Drugs for Treating Hyperuricemia Annual Revenue by Geographic Region  
(2021-2026)

4.2 World Historic Drugs for Treating Hyperuricemia Market Size by Country/Region  
(2021-2026)

4.2.1 Global Drugs for Treating Hyperuricemia Annual Sales by Country/Region  
(2021-2026)

4.2.2 Global Drugs for Treating Hyperuricemia Annual Revenue by Country/Region (2021-2026)

4.3 Americas Drugs for Treating Hyperuricemia Sales Growth

4.4 APAC Drugs for Treating Hyperuricemia Sales Growth

4.5 Europe Drugs for Treating Hyperuricemia Sales Growth

4.6 Middle East & Africa Drugs for Treating Hyperuricemia Sales Growth

## **5 AMERICAS**

5.1 Americas Drugs for Treating Hyperuricemia Sales by Country

5.1.1 Americas Drugs for Treating Hyperuricemia Sales by Country (2021-2026)

5.1.2 Americas Drugs for Treating Hyperuricemia Revenue by Country (2021-2026)

5.2 Americas Drugs for Treating Hyperuricemia Sales by Type (2021-2026)

5.3 Americas Drugs for Treating Hyperuricemia Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

## **6 APAC**

6.1 APAC Drugs for Treating Hyperuricemia Sales by Region

6.1.1 APAC Drugs for Treating Hyperuricemia Sales by Region (2021-2026)

6.1.2 APAC Drugs for Treating Hyperuricemia Revenue by Region (2021-2026)

6.2 APAC Drugs for Treating Hyperuricemia Sales by Type (2021-2026)

6.3 APAC Drugs for Treating Hyperuricemia Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

## **7 EUROPE**

7.1 Europe Drugs for Treating Hyperuricemia by Country

7.1.1 Europe Drugs for Treating Hyperuricemia Sales by Country (2021-2026)

7.1.2 Europe Drugs for Treating Hyperuricemia Revenue by Country (2021-2026)

- 7.2 Europe Drugs for Treating Hyperuricemia Sales by Type (2021-2026)
- 7.3 Europe Drugs for Treating Hyperuricemia Sales by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

## **8 MIDDLE EAST & AFRICA**

- 8.1 Middle East & Africa Drugs for Treating Hyperuricemia by Country
  - 8.1.1 Middle East & Africa Drugs for Treating Hyperuricemia Sales by Country (2021-2026)
  - 8.1.2 Middle East & Africa Drugs for Treating Hyperuricemia Revenue by Country (2021-2026)
- 8.2 Middle East & Africa Drugs for Treating Hyperuricemia Sales by Type (2021-2026)
- 8.3 Middle East & Africa Drugs for Treating Hyperuricemia Sales by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Drugs for Treating Hyperuricemia
- 10.3 Manufacturing Process Analysis of Drugs for Treating Hyperuricemia
- 10.4 Industry Chain Structure of Drugs for Treating Hyperuricemia

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

- 11.1 Sales Channel
  - 11.1.1 Direct Channels
  - 11.1.2 Indirect Channels
- 11.2 Drugs for Treating Hyperuricemia Distributors
- 11.3 Drugs for Treating Hyperuricemia Customer

## **12 WORLD FORECAST REVIEW FOR DRUGS FOR TREATING HYPERURICEMIA BY GEOGRAPHIC REGION**

- 12.1 Global Drugs for Treating Hyperuricemia Market Size Forecast by Region
  - 12.1.1 Global Drugs for Treating Hyperuricemia Forecast by Region (2027-2032)
  - 12.1.2 Global Drugs for Treating Hyperuricemia Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global Drugs for Treating Hyperuricemia Forecast by Type (2027-2032)
- 12.7 Global Drugs for Treating Hyperuricemia Forecast by Application (2027-2032)

## **13 KEY PLAYERS ANALYSIS**

- 13.1 Teva
  - 13.1.1 Teva Company Information
  - 13.1.2 Teva Drugs for Treating Hyperuricemia Product Portfolios and Specifications
  - 13.1.3 Teva Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.1.4 Teva Main Business Overview
  - 13.1.5 Teva Latest Developments
- 13.2 Mylan Pharmaceuticals
  - 13.2.1 Mylan Pharmaceuticals Company Information
  - 13.2.2 Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolios and Specifications
  - 13.2.3 Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.2.4 Mylan Pharmaceuticals Main Business Overview
  - 13.2.5 Mylan Pharmaceuticals Latest Developments
- 13.3 Takeda Pharmaceuticals
  - 13.3.1 Takeda Pharmaceuticals Company Information

13.3.2 Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolios and Specifications

13.3.3 Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Takeda Pharmaceuticals Main Business Overview

13.3.5 Takeda Pharmaceuticals Latest Developments

13.4 Sanwa Kagaku Kenkyusho

13.4.1 Sanwa Kagaku Kenkyusho Company Information

13.4.2 Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Product Portfolios and Specifications

13.4.3 Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Sanwa Kagaku Kenkyusho Main Business Overview

13.4.5 Sanwa Kagaku Kenkyusho Latest Developments

13.5 Towa Pharmaceutical

13.5.1 Towa Pharmaceutical Company Information

13.5.2 Towa Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolios and Specifications

13.5.3 Towa Pharmaceutical Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Towa Pharmaceutical Main Business Overview

13.5.5 Towa Pharmaceutical Latest Developments

13.6 Toa Eiyo

13.6.1 Toa Eiyo Company Information

13.6.2 Toa Eiyo Drugs for Treating Hyperuricemia Product Portfolios and Specifications

13.6.3 Toa Eiyo Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Toa Eiyo Main Business Overview

13.6.5 Toa Eiyo Latest Developments

13.7 AstraZeneca

13.7.1 AstraZeneca Company Information

13.7.2 AstraZeneca Drugs for Treating Hyperuricemia Product Portfolios and Specifications

13.7.3 AstraZeneca Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 AstraZeneca Main Business Overview

13.7.5 AstraZeneca Latest Developments

13.8 Mochida Pharmaceutical

- 13.8.1 Mochida Pharmaceutical Company Information
- 13.8.2 Mochida Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolios and Specifications
- 13.8.3 Mochida Pharmaceutical Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.8.4 Mochida Pharmaceutical Main Business Overview
- 13.8.5 Mochida Pharmaceutical Latest Developments
- 13.9 Lannett Company
  - 13.9.1 Lannett Company Company Information
  - 13.9.2 Lannett Company Drugs for Treating Hyperuricemia Product Portfolios and Specifications
  - 13.9.3 Lannett Company Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.9.4 Lannett Company Main Business Overview
  - 13.9.5 Lannett Company Latest Developments
- 13.10 Horizo??n Therapeutics
  - 13.10.1 Horizo??n Therapeutics Company Information
  - 13.10.2 Horizo??n Therapeutics Drugs for Treating Hyperuricemia Product Portfolios and Specifications
  - 13.10.3 Horizo??n Therapeutics Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.10.4 Horizo??n Therapeutics Main Business Overview
  - 13.10.5 Horizo??n Therapeutics Latest Developments
- 13.11 Sanofi
  - 13.11.1 Sanofi Company Information
  - 13.11.2 Sanofi Drugs for Treating Hyperuricemia Product Portfolios and Specifications
  - 13.11.3 Sanofi Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.11.4 Sanofi Main Business Overview
  - 13.11.5 Sanofi Latest Developments
- 13.12 GSK
  - 13.12.1 GSK Company Information
  - 13.12.2 GSK Drugs for Treating Hyperuricemia Product Portfolios and Specifications
  - 13.12.3 GSK Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.12.4 GSK Main Business Overview
  - 13.12.5 GSK Latest Developments
- 13.13 Fuji Yakuhin
  - 13.13.1 Fuji Yakuhin Company Information

13.13.2 Fuji Yakuhin Drugs for Treating Hyperuricemia Product Portfolios and Specifications

13.13.3 Fuji Yakuhin Drugs for Treating Hyperuricemia Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Fuji Yakuhin Main Business Overview

13.13.5 Fuji Yakuhin Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

- Table 1. Drugs for Treating Hyperuricemia Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Table 2. Drugs for Treating Hyperuricemia Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Uric Acid Production Inhibitors
- Table 4. Major Players of Urate-stimulating Excretion Agents
- Table 5. Major Players of Other
- Table 6. Global Drugs for Treating Hyperuricemia Sales by Type (2021-2026) & (K Units)
- Table 7. Global Drugs for Treating Hyperuricemia Sales Market Share by Type (2021-2026)
- Table 8. Global Drugs for Treating Hyperuricemia Revenue by Type (2021-2026) & (\$ million)
- Table 9. Global Drugs for Treating Hyperuricemia Revenue Market Share by Type (2021-2026)
- Table 10. Global Drugs for Treating Hyperuricemia Sale Price by Type (2021-2026) & (US\$/Unit)
- Table 11. Global Drugs for Treating Hyperuricemia Sale by Application (2021-2026) & (K Units)
- Table 12. Global Drugs for Treating Hyperuricemia Sale Market Share by Application (2021-2026)
- Table 13. Global Drugs for Treating Hyperuricemia Revenue by Application (2021-2026) & (\$ million)
- Table 14. Global Drugs for Treating Hyperuricemia Revenue Market Share by Application (2021-2026)
- Table 15. Global Drugs for Treating Hyperuricemia Sale Price by Application (2021-2026) & (US\$/Unit)
- Table 16. Global Drugs for Treating Hyperuricemia Sales by Company (2021-2026) & (K Units)
- Table 17. Global Drugs for Treating Hyperuricemia Sales Market Share by Company (2021-2026)
- Table 18. Global Drugs for Treating Hyperuricemia Revenue by Company (2021-2026) & (\$ millions)
- Table 19. Global Drugs for Treating Hyperuricemia Revenue Market Share by Company (2021-2026)

Table 20. Global Drugs for Treating Hyperuricemia Sale Price by Company (2021-2026) & (US\$/Unit)

Table 21. Key Manufacturers Drugs for Treating Hyperuricemia Producing Area Distribution and Sales Area

Table 22. Players Drugs for Treating Hyperuricemia Products Offered

Table 23. Drugs for Treating Hyperuricemia Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 24. New Products and Potential Entrants

Table 25. Market M&A Activity & Strategy

Table 26. Global Drugs for Treating Hyperuricemia Sales by Geographic Region (2021-2026) & (K Units)

Table 27. Global Drugs for Treating Hyperuricemia Sales Market Share Geographic Region (2021-2026)

Table 28. Global Drugs for Treating Hyperuricemia Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 29. Global Drugs for Treating Hyperuricemia Revenue Market Share by Geographic Region (2021-2026)

Table 30. Global Drugs for Treating Hyperuricemia Sales by Country/Region (2021-2026) & (K Units)

Table 31. Global Drugs for Treating Hyperuricemia Sales Market Share by Country/Region (2021-2026)

Table 32. Global Drugs for Treating Hyperuricemia Revenue by Country/Region (2021-2026) & (\$ millions)

Table 33. Global Drugs for Treating Hyperuricemia Revenue Market Share by Country/Region (2021-2026)

Table 34. Americas Drugs for Treating Hyperuricemia Sales by Country (2021-2026) & (K Units)

Table 35. Americas Drugs for Treating Hyperuricemia Sales Market Share by Country (2021-2026)

Table 36. Americas Drugs for Treating Hyperuricemia Revenue by Country (2021-2026) & (\$ millions)

Table 37. Americas Drugs for Treating Hyperuricemia Sales by Type (2021-2026) & (K Units)

Table 38. Americas Drugs for Treating Hyperuricemia Sales by Application (2021-2026) & (K Units)

Table 39. APAC Drugs for Treating Hyperuricemia Sales by Region (2021-2026) & (K Units)

Table 40. APAC Drugs for Treating Hyperuricemia Sales Market Share by Region (2021-2026)

Table 41. APAC Drugs for Treating Hyperuricemia Revenue by Region (2021-2026) & (\$ millions)

Table 42. APAC Drugs for Treating Hyperuricemia Sales by Type (2021-2026) & (K Units)

Table 43. APAC Drugs for Treating Hyperuricemia Sales by Application (2021-2026) & (K Units)

Table 44. Europe Drugs for Treating Hyperuricemia Sales by Country (2021-2026) & (K Units)

Table 45. Europe Drugs for Treating Hyperuricemia Revenue by Country (2021-2026) & (\$ millions)

Table 46. Europe Drugs for Treating Hyperuricemia Sales by Type (2021-2026) & (K Units)

Table 47. Europe Drugs for Treating Hyperuricemia Sales by Application (2021-2026) & (K Units)

Table 48. Middle East & Africa Drugs for Treating Hyperuricemia Sales by Country (2021-2026) & (K Units)

Table 49. Middle East & Africa Drugs for Treating Hyperuricemia Revenue Market Share by Country (2021-2026)

Table 50. Middle East & Africa Drugs for Treating Hyperuricemia Sales by Type (2021-2026) & (K Units)

Table 51. Middle East & Africa Drugs for Treating Hyperuricemia Sales by Application (2021-2026) & (K Units)

Table 52. Key Market Drivers & Growth Opportunities of Drugs for Treating Hyperuricemia

Table 53. Key Market Challenges & Risks of Drugs for Treating Hyperuricemia

Table 54. Key Industry Trends of Drugs for Treating Hyperuricemia

Table 55. Drugs for Treating Hyperuricemia Raw Material

Table 56. Key Suppliers of Raw Materials

Table 57. Drugs for Treating Hyperuricemia Distributors List

Table 58. Drugs for Treating Hyperuricemia Customer List

Table 59. Global Drugs for Treating Hyperuricemia Sales Forecast by Region (2027-2032) & (K Units)

Table 60. Global Drugs for Treating Hyperuricemia Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 61. Americas Drugs for Treating Hyperuricemia Sales Forecast by Country (2027-2032) & (K Units)

Table 62. Americas Drugs for Treating Hyperuricemia Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 63. APAC Drugs for Treating Hyperuricemia Sales Forecast by Region

(2027-2032) & (K Units)

Table 64. APAC Drugs for Treating Hyperuricemia Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 65. Europe Drugs for Treating Hyperuricemia Sales Forecast by Country (2027-2032) & (K Units)

Table 66. Europe Drugs for Treating Hyperuricemia Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 67. Middle East & Africa Drugs for Treating Hyperuricemia Sales Forecast by Country (2027-2032) & (K Units)

Table 68. Middle East & Africa Drugs for Treating Hyperuricemia Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 69. Global Drugs for Treating Hyperuricemia Sales Forecast by Type (2027-2032) & (K Units)

Table 70. Global Drugs for Treating Hyperuricemia Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 71. Global Drugs for Treating Hyperuricemia Sales Forecast by Application (2027-2032) & (K Units)

Table 72. Global Drugs for Treating Hyperuricemia Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 73. Teva Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 74. Teva Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 75. Teva Drugs for Treating Hyperuricemia Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 76. Teva Main Business

Table 77. Teva Latest Developments

Table 78. Mylan Pharmaceuticals Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 79. Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 80. Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 81. Mylan Pharmaceuticals Main Business

Table 82. Mylan Pharmaceuticals Latest Developments

Table 83. Takeda Pharmaceuticals Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 84. Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 85. Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 86. Takeda Pharmaceuticals Main Business

Table 87. Takeda Pharmaceuticals Latest Developments

Table 88. Sanwa Kagaku Kenkyusho Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 89. Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 90. Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 91. Sanwa Kagaku Kenkyusho Main Business

Table 92. Sanwa Kagaku Kenkyusho Latest Developments

Table 93. Towa Pharmaceutical Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 94. Towa Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 95. Towa Pharmaceutical Drugs for Treating Hyperuricemia Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 96. Towa Pharmaceutical Main Business

Table 97. Towa Pharmaceutical Latest Developments

Table 98. Toa Eiyo Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 99. Toa Eiyo Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 100. Toa Eiyo Drugs for Treating Hyperuricemia Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 101. Toa Eiyo Main Business

Table 102. Toa Eiyo Latest Developments

Table 103. AstraZeneca Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 104. AstraZeneca Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 105. AstraZeneca Drugs for Treating Hyperuricemia Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 106. AstraZeneca Main Business

Table 107. AstraZeneca Latest Developments

Table 108. Mochida Pharmaceutical Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 109. Mochida Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 110. Mochida Pharmaceutical Drugs for Treating Hyperuricemia Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 111. Mochida Pharmaceutical Main Business

Table 112. Mochida Pharmaceutical Latest Developments

Table 113. Lannett Company Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 114. Lannett Company Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 115. Lannett Company Drugs for Treating Hyperuricemia Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 116. Lannett Company Main Business

Table 117. Lannett Company Latest Developments

Table 118. Horizon Therapeutics Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 119. Horizon Therapeutics Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 120. Horizon Therapeutics Drugs for Treating Hyperuricemia Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 121. Horizon Therapeutics Main Business

Table 122. Horizon Therapeutics Latest Developments

Table 123. Sanofi Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 124. Sanofi Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 125. Sanofi Drugs for Treating Hyperuricemia Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 126. Sanofi Main Business

Table 127. Sanofi Latest Developments

Table 128. GSK Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 129. GSK Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 130. GSK Drugs for Treating Hyperuricemia Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 131. GSK Main Business

Table 132. GSK Latest Developments

Table 133. Fuji Yakuhin Basic Information, Drugs for Treating Hyperuricemia Manufacturing Base, Sales Area and Its Competitors

Table 134. Fuji Yakuhin Drugs for Treating Hyperuricemia Product Portfolios and Specifications

Table 135. Fuji Yakuhin Drugs for Treating Hyperuricemia Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 136. Fuji Yakuhin Main Business

Table 137. Fuji Yakuhin Latest Developments

## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of Drugs for Treating Hyperuricemia
- Figure 2. Drugs for Treating Hyperuricemia Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Drugs for Treating Hyperuricemia Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Drugs for Treating Hyperuricemia Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Drugs for Treating Hyperuricemia Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Drugs for Treating Hyperuricemia Sales Market Share by Country/Region (2025)
- Figure 10. Drugs for Treating Hyperuricemia Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Uric Acid Production Inhibitors
- Figure 12. Product Picture of Urate-stimulating Excretion Agents
- Figure 13. Product Picture of Other
- Figure 14. Global Drugs for Treating Hyperuricemia Sales Market Share by Type in 2026
- Figure 15. Global Drugs for Treating Hyperuricemia Revenue Market Share by Type (2021-2026)
- Figure 16. Drugs for Treating Hyperuricemia Consumed in Hospitals and Clinics
- Figure 17. Global Drugs for Treating Hyperuricemia Market: Hospitals and Clinics (2021-2026) & (K Units)
- Figure 18. Drugs for Treating Hyperuricemia Consumed in Retail Pharmacies
- Figure 19. Global Drugs for Treating Hyperuricemia Market: Retail Pharmacies (2021-2026) & (K Units)
- Figure 20. Drugs for Treating Hyperuricemia Consumed in Other
- Figure 21. Global Drugs for Treating Hyperuricemia Market: Other (2021-2026) & (K Units)
- Figure 22. Global Drugs for Treating Hyperuricemia Sale Market Share by Application (2025)
- Figure 23. Global Drugs for Treating Hyperuricemia Revenue Market Share by Application in 2026

Figure 24. Drugs for Treating Hyperuricemia Sales by Company in 2026 (K Units)

Figure 25. Global Drugs for Treating Hyperuricemia Sales Market Share by Company in 2026

Figure 26. Drugs for Treating Hyperuricemia Revenue by Company in 2026 (\$ millions)

Figure 27. Global Drugs for Treating Hyperuricemia Revenue Market Share by Company in 2026

Figure 28. Global Drugs for Treating Hyperuricemia Sales Market Share by Geographic Region (2021-2026)

Figure 29. Global Drugs for Treating Hyperuricemia Revenue Market Share by Geographic Region in 2026

Figure 30. Americas Drugs for Treating Hyperuricemia Sales 2021-2026 (K Units)

Figure 31. Americas Drugs for Treating Hyperuricemia Revenue 2021-2026 (\$ millions)

Figure 32. APAC Drugs for Treating Hyperuricemia Sales 2021-2026 (K Units)

Figure 33. APAC Drugs for Treating Hyperuricemia Revenue 2021-2026 (\$ millions)

Figure 34. Europe Drugs for Treating Hyperuricemia Sales 2021-2026 (K Units)

Figure 35. Europe Drugs for Treating Hyperuricemia Revenue 2021-2026 (\$ millions)

Figure 36. Middle East & Africa Drugs for Treating Hyperuricemia Sales 2021-2026 (K Units)

Figure 37. Middle East & Africa Drugs for Treating Hyperuricemia Revenue 2021-2026 (\$ millions)

Figure 38. Americas Drugs for Treating Hyperuricemia Sales Market Share by Country in 2026

Figure 39. Americas Drugs for Treating Hyperuricemia Revenue Market Share by Country (2021-2026)

Figure 40. Americas Drugs for Treating Hyperuricemia Sales Market Share by Type (2021-2026)

Figure 41. Americas Drugs for Treating Hyperuricemia Sales Market Share by Application (2021-2026)

Figure 42. United States Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 43. Canada Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 44. Mexico Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 45. Brazil Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 46. APAC Drugs for Treating Hyperuricemia Sales Market Share by Region in 2026

Figure 47. APAC Drugs for Treating Hyperuricemia Revenue Market Share by Region

(2021-2026)

Figure 48. APAC Drugs for Treating Hyperuricemia Sales Market Share by Type

(2021-2026)

Figure 49. APAC Drugs for Treating Hyperuricemia Sales Market Share by Application

(2021-2026)

Figure 50. China Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 51. Japan Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 52. South Korea Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 53. Southeast Asia Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 54. India Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 55. Australia Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 56. China Taiwan Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 57. Europe Drugs for Treating Hyperuricemia Sales Market Share by Country in 2026

Figure 58. Europe Drugs for Treating Hyperuricemia Revenue Market Share by Country (2021-2026)

Figure 59. Europe Drugs for Treating Hyperuricemia Sales Market Share by Type (2021-2026)

Figure 60. Europe Drugs for Treating Hyperuricemia Sales Market Share by Application (2021-2026)

Figure 61. Germany Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 62. France Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 63. UK Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 64. Italy Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 65. Russia Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 66. Middle East & Africa Drugs for Treating Hyperuricemia Sales Market Share by Country (2021-2026)

Figure 67. Middle East & Africa Drugs for Treating Hyperuricemia Sales Market Share by Type (2021-2026)

Figure 68. Middle East & Africa Drugs for Treating Hyperuricemia Sales Market Share by Application (2021-2026)

Figure 69. Egypt Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 70. South Africa Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 71. Israel Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 72. Turkey Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 73. GCC Countries Drugs for Treating Hyperuricemia Revenue Growth 2021-2026 (\$ millions)

Figure 74. Manufacturing Cost Structure Analysis of Drugs for Treating Hyperuricemia in 2026

Figure 75. Manufacturing Process Analysis of Drugs for Treating Hyperuricemia

Figure 76. Industry Chain Structure of Drugs for Treating Hyperuricemia

Figure 77. Channels of Distribution

Figure 78. Global Drugs for Treating Hyperuricemia Sales Market Forecast by Region (2027-2032)

Figure 79. Global Drugs for Treating Hyperuricemia Revenue Market Share Forecast by Region (2027-2032)

Figure 80. Global Drugs for Treating Hyperuricemia Sales Market Share Forecast by Type (2027-2032)

Figure 81. Global Drugs for Treating Hyperuricemia Revenue Market Share Forecast by Type (2027-2032)

Figure 82. Global Drugs for Treating Hyperuricemia Sales Market Share Forecast by Application (2027-2032)

Figure 83. Global Drugs for Treating Hyperuricemia Revenue Market Share Forecast by Application (2027-2032)

## I would like to order

Product name: Global Drugs for Treating Hyperuricemia Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G49ED5DD27EBEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G49ED5DD27EBEN.html>